22:56 , Jul 19, 2017 |  BC Extra  |  Clinical News

Fujifilm AD candidate fails in Phase II study

Fujifilm Holdings Corp. (Tokyo:4901) said T-817MA failed to significantly improve cognition or global clinical function vs. placebo in a Phase II study to treat mild to moderate Alzheimer's disease, missing the trial's primary endpoints. The...
00:28 , Apr 29, 2015 |  BC Extra  |  Politics & Policy

FDA supports C-Path's AD, PD biomarkers

FDA issued Letters of Support to the Coalition Against Major Diseases (CAMD) consortium of the Critical Path Institute (C-Path) for the use of five biomarkers to help select early stage Parkinson's and Alzheimer's disease patients...
07:00 , May 30, 2011 |  BioCentury  |  Emerging Company Profile

QR: Power of positivity

QR Pharma Inc. has in-licensed a pair of compounds for cognitive impairment and Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety. The more advanced of the two compounds...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Company News

Applied NeuroSolutions diagnostic, neurology news

Applied NeuroSolutions hired William Blair & Co. LLC to explore strategic alternatives, including partnerships. The company markets P-Tau 231 for research use. The antibody-based test measures levels of phosphorylated tau (p-tau) 231 in cerebrospinal...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

p-tau 231 ELISA test neurology data

In a retrospective analysis of 145 European subjects, CSF levels of p-tau 231 predicted whether a patient would convert to AD from MCI (p=0.001). The analysis included 43 MCI patients that converted to AD, 45...